Streptococcal infections of skin and soft tissues

New England Journal of Medicine

Volumn 334, Issue 4, 1996, Pages 240-245

  Bisno, Alan L ^a,b   Stevens, Dennis L ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Boise VA Medical Center   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; CLINDAMYCIN; PENICILLIN G;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CELLULITIS; ERYSIPELAS; HUMAN; IMPETIGO; PATHOGENESIS; PRIORITY JOURNAL; PYODERMA; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME;

ANTI-BACTERIAL AGENTS; CELLULITIS; ERYSIPELAS; FASCIITIS, NECROTIZING; HUMANS; PYODERMA; SHOCK, SEPTIC; SKIN DISEASES, BACTERIAL; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 0030034479     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199601253340407     Document Type: Review

References (51)

1. Bisno AL. Group A streptococcal infections and acute rheumatic fever N Engl J Med 1991;325:783-93.
2. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992;14,2-11.
3. Kaplan EL, Wannamaker LW. Suppression of the antistreptolysin O response by cholesterol and by lipid extracts of rabbit skin. J Exp Med 1976; 144:754-67.
4. Bisno AL, Nelson KE, Waytz P, Brunt I. Factors influencing serum antibody responses in streptococcal pyoderma. J Lab Clin Med 1973;81.410-20.
5. Kaplan EL, Anthony BF, Chapman SS, Ayoub EM, Wannamaker LW. The influence of the site of infection on the immune response to group A streptococci. J Clin Invest 1970;49:1405-14.
6. Bisno AL, Pearce IA, Wall HP, Moody MD, Stollerman GH. Contrasting epidemiology of acute rheumatic fever and acute glomerulonephritis: nature of the antecedent streptococcal infection. N Engl J Med 1970,283:561-5.
7. Feingold DS Staphylococcal and streptococcal pyodermas. Semin Dermatol 1993,12:331-5.
8. Demidovich CW, Wittler RR, Ruff ME, Bass JW, Browning WC. Impetigo, current etiology and comparison of penicillin, erythromycin, and cephalexin therapies Am J Dis Child 1990;144:1313-5.
9. Mertz PM, Marshall DA, Eaglstein WH, Piovanetti Y, Montalvo J. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Arch Dermatol 1989;125:1069-73.
10. Lasch EE, Frankel V, Vardy PA, Bergner-Rabinowitz S, Ofek I, Rabinowitz K. Epidemic glomerulonephritis in Israel. J Infect Dis 1971;124.141-7.
11. Baddour LM, Bisno AL. Recurrent cellulitis after saphenous venectomy for coronary bypass surgery. Ann Intern Med 1982;97:493-6.
12. Lentnek AL, Giger O, O'Rourke E. Group A beta-hemolytic streptococcal bacteremia and intravenous substance abuse: a growing clinical problem? Arch Intern Med 1990;150.89-93.
13. Baddour LM, Bisno AL. Non-group A beta-hemolytic streptococcal cellulitis: association with venous and lymphatic compromise. Am J Med 1985, 79:155-9.
14. Craven DE, Rixinger AI, Bisno AL, Goularte TA, McCabe WR. Bacteremia caused by group G streptococci in parenteral drug abusers: epidemiological and clinical aspects. J Infect Dis 1986;153:988-92.
15. Bisno AL, Craven DE, McCabe WR M proteins of group G streptococci isolated from bacteremic human infections Infect Immun 1987;55 753-7.
16. Stevens DL. Streptococcal infections of skin and soft tissues. In: Mandell GL, Stevens DL, eds Atlas of infectious diseases. Vol. 2 Skin, soft tissue, bone, and joint infections. Philadelphia: Current Medicine, 1995:3.1-3 11
17. Chartier C, Grosshans E Erysipelas Int J Dermatol 1990;29:459-67.
18. Binnick AN, Klein RB, Baughman RD. Recurrent erysipelas caused by group B streptococcus organisms. Arch Dermatol 1980;116:798-9.
19. Hook EW III, Hooton TM, Horton CA, Coyle MB, Ramsey PG, Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986;146:295-7
20. Kiehlbauch JA, Tauxe RV, Baker CN, Wachsmuth IK. Helicobacter cinaedi-associated bacteremia and cellulitis in immunocompromised patients. Ann Intern Med 1994;121:90-3.
21. Swartz MN Cellulitis and subcutaneous tissue infections In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases 4th ed New York: Churchill Livingstone, 1995.909-29.
22. Idem Myositis. In: Mandell GL, Bennett JE, Dolin R, eds Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995 929-36.
23. Chelsom J, Halstensen A, Haga T, Hoiby EA Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features Lancet 1994,344.1111-5
24. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989;321:1-7.
25. Stevens DL. Invasive group A streptococcal infections the past, present and future. Pediatr Infect Dis J 1994; 13 561-6.
26. Meleney FL. Hemolytic streptococcus gangrene. Arch Surg 1924;9:317-64
27. Zittergruen M, Grose C. Magnetic resonance imaging for early diagnosis of necrotizing fasciitis. Pediatr Emerg Care 1993;9:26-S
28. Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis: the use of frozen-section biopsy. N Engl J Med 1984,310.1689-93.
29. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition JAMA 1993;269:390-1.
30. Chapnick EK, Gradon JD, Lutwick LI, et al. Streptococcal toxic shock syndrome due to noninvasive pharyngitis. Clin Infecl Dis 1992;14.1074-7.
31. Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 1992;166:31-7.
32. Schwartz B, Facklain RR, Breiman RF. Changing epidemiology of group A streptococcal infection in the USA Lancet 1990;336.1167-71.
33. Martin PR, Hoiby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis 1990,22:421-9.
34. Gaworzewska E, Colman G. Changes in the pattern of infection caused by Streptococcus pyogenes. Epidemiol Infect 1988;100:257-69.
35. Norrby-Teglund A, Newton D, Kotb M, Holm SE, Norgren M. Superantigenic properties of the group A streptococcal exotoxin SpeF (MF). Infect Immun 1994;62:5227-33.
36. Kim YB, Watson DW. Streptococcal exotoxins: biological and pathological properties. In. Wannamaker LW, Matsen JM, eds. Streptococci and streptococcal diseases: recognition, understanding, and management New York, Academic Press, 1972:33-50.
37. Hackett SP, Stevens DL. Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis 1992;165:879-85.
38. Fast DJ, Schlievert PM, Nelson RD. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun 1989;57:291-4.
39. Kotb M, Ohnishi H, Majumdar G, et al Temporal relationship of cytokine release by peripheral blood mononuclear cells stimulated by the streptococcal superantigen pep M5. Infect Immun 1993;61:1194-201.
40. Farley JD, Woo V, Shaw C, Smith JA Invasive streptococcal disease in British Columbia. Can Dis Wkly Rep 1990,16:257-9.
41. Mollick JA, Miller GG, Musser JM, Cook RG, Grossman D, Rich RR. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J Clin Invest 1993;92:710-9.
42. Iwasaki M, Igarashi H, Hinuma Y, Yutsudo T. Cloning, characterization and overexpression of a Streptococcus pyogenes gene encoding a new type of mitogenic factor. FEBS Lett 1993,331:187-92.
43. Eagle H Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952;13:389-99.
44. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis J Infect Dis 1988;158 23-8
45. Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993;167:1401-5.
46. Stevens DL, Maier KA, Mitten JE. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 1987,31.213-8.
47. Gemmell CG, Peterson PK, Schmeling D, et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981;67:1249-56.
48. Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response Clin Infect Dis 1995;20:Suppl 2:S154-S157.
49. Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery 1990,108 847-50.
50. Barry W, Hudgins L, Donta ST, Pesanti EL Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992;267 3315-6.
51. Yong JM Necrotising fasciitis. Lancet 1994;343 1427.